Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Policy / Regulatory

CDE Reference Standards 101st Batch Seeks Public Feedback

Fineline Cube Dec 23, 2025
Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Fineline Cube Dec 23, 2025
Company Drug

3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery

Fineline Cube Dec 23, 2025
Company Deals

Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform

Fineline Cube Aug 17, 2023

US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan...

Company Digital

JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report

Fineline Cube Aug 17, 2023

JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...

Company

Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law

Fineline Cube Aug 17, 2023

Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of...

Company Drug

Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis

Fineline Cube Aug 16, 2023

China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...

Company

Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom

Fineline Cube Aug 16, 2023

Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of...

Company

Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment

Fineline Cube Aug 16, 2023

Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the...

Company Drug

Yingli Pharma’s Linperlislib Receives Priority Review Status for Lymphoma Treatments

Fineline Cube Aug 16, 2023

US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US...

Company

Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending

Fineline Cube Aug 16, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and...

Company Deals

Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal

Fineline Cube Aug 16, 2023

Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...

Company Drug

Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept

Fineline Cube Aug 16, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory...

Company Deals

Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies

Fineline Cube Aug 16, 2023

Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development

Fineline Cube Aug 16, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced a new cooperation agreement with...

Company Drug

YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment

Fineline Cube Aug 16, 2023

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...

Company Drug

Everest Medicines’ Partner Venatorx Pharmaceuticals Receives FDA Priority Review for Cefepime-Taniborbactam

Fineline Cube Aug 16, 2023

China-based Everest Medicines (HKG: 1952) announced that its partner, Venatorx Pharmaceuticals, has received acceptance from...

Company

CStone Pharmaceuticals Reports 2023 Interim Financials and Business Milestones

Fineline Cube Aug 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced its 2023 interim financial results alongside key business...

Company Deals

HitGen Inc. Partners with Nested Therapeutics for Precision Medicine Research

Fineline Cube Aug 15, 2023

China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision...

Company Drug

Simcere Pharmaceutical’s Cosela Receives NMPA Review for ES-SCLC Indication

Fineline Cube Aug 15, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Suzhou Leadsynbio Secures Series D Funding to Boost R&D and Market Presence

Fineline Cube Aug 15, 2023

Suzhou Leadsynbio Technology Co., Ltd, a specialist in synthetic biology, has reported raised hundreds of...

Company Drug

SinoMab BioScience Receives NMPA Approval for Phase I Clinical Study of SM17 Asthma Therapy

Fineline Cube Aug 15, 2023

Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received...

Company Deals

Jiangsu Hengrui Pharmaceuticals Strikes Licensing Deal with One Bio Inc. for TSLP-Targeted mAb SHR1905

Fineline Cube Aug 15, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced a significant licensing agreement with...

Posts pagination

1 … 423 424 425 … 601

Recent updates

  • Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
  • Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
  • 3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery
  • Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment
  • Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Company Drug

3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery

Company Drug

Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.